Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant.
about
Customized targeted therapy in Hodgkin lymphoma: hype or hope?A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.Relapsed Hodgkin lymphoma: management strategiesImmune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression.Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
P2860
Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Early thymus and activation-re ...... tologous stem cell transplant.
@en
Early thymus and activation-regulated chemokine
@nl
type
label
Early thymus and activation-re ...... tologous stem cell transplant.
@en
Early thymus and activation-regulated chemokine
@nl
prefLabel
Early thymus and activation-re ...... tologous stem cell transplant.
@en
Early thymus and activation-regulated chemokine
@nl
P2093
P2860
P1433
P1476
Early thymus and activation-re ...... tologous stem cell transplant.
@en
P2093
Anas Younes
Andreas Engert
Andy K Hsu
Anna Sureda
David S Ritchie
Denise Williams
H Miles Prince
Margaret Squier
Paula Savage
P2860
P304
P356
10.3109/10428194.2013.820287
P577
2013-08-05T00:00:00Z